Authors: Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM
PMID: 32662690 PMCID: PMC7441798 DOI: 10.1080/14787210.2020.1794819
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected almost 2.5 million people worldwide with almost 170,000 deaths reported to date. So far, there is scarce evidence for the current treatment options available for COVID-19. Vitamin C has previously been used for treatment of severe sepsis and septic shock. We reviewed the feasibility of using vitamin C in the setting of COVID-19 in a series of patients.
Methods: We sequentially identified a series of patients who were requiring at least 30% of FiO2 or more who received IV vitamin C as part of the COVID-19 treatment and analyzed their demographic and clinical characteristics. We compared inflammatory markers pre and post treatment including D-dimer and ferritin.
Results: We identified a total of 17 patients who received IV vitamin C for COVID-19. The inpatient mortality rate in this series was 12% with 17.6% rates of intubation and mechanical ventilation. We noted a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration.
Conclusion: The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.
Keywords: COVID-19; coronavirus; mortality; sepsis; vitamin C.
Source: https://pubmed.ncbi.nlm.nih.gov/32662690/
Archive: https://archive.ph/FtSVI
